Prothena(PRTA)
DUBLIN 2, IrelandBiotechnology
Focus: Prothena is a Dublin-based public biotech focused on monoclonal antibodies targeting neurology and immunology indications. The company operates at clinical stage with a diversified pipeline spanning Parkinson's disease, amyloidosis, and psoriasis.
Profile data last refreshed 15h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Prothena
AI assessmentNot HiringNo open roles listed right now. Follow Prothena to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Prothena's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Revenue
$91M
Pipeline & Clinical Trials
Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinso
Parkinson's DiseaseClinical Trials (1)
NCT03043768Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease
N/AHelp build intelligence for Prothena
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.